Company: PFSA
Filing Date: 2025-02-12
Form Type: S-4/A
Source: 0001213900-25-012354
Chunk: 450

Company: Profusa, Inc.
Filing Date: 2025-02-12
Form: S-4/A
Chunk 450
---
 use these needles to administer flu shots and other 255 vaccines. At the same time, physicians can still leverage existing CPT codes related to interpretation of CGM data and we have, in parallel, initiated steps for CPT codes related to our sensor insertion. We will target both public and private payors for coverage. Since our launch, we have significantly devoted all of our resources to research and development, as well as all clinical study activities related but not limited to Lumee Oxygen, Lumee Glucose and prototypes for sensors of at least eight other analytes. We have also invested, on a smaller scale, in making sales of Lumee Oxygen for research- use only clients, which include entities working with animal models. Furthermore, we also performed research and development under government grants. Since inception, we have incurred recurring annual losses from operations. For the years ended December 31, 2023 and 2022, we incurred a net loss of $10.3 million and $20.2 million, respectively. During the years ended December 31, 2023 and 2022, we have used $4.4 million and $7.7 million, respectively, of cash in our operating activities. For the nine -monthsended September 30, 2024 and 2023, we incurred a net loss of $7.0 million and $7.0 million, respectively. During the nine -monthsended September 30, 2024 and 2023, we have used $1.8 million and $3.7 million, respectively, of cash in our operating activities. We have notes and loans payable and interest due of $45.7 million within twelve months of September 30, 2024. We have been able to finance our operations primarily with the proceeds from the issuance of equity and debt instruments and to a lesser extent, revenues from government grants. For the year ending December 31, 2023, we obtained net cash from financing activities of $4.5 million compared to $6.9 million for the same period in 2022. For the nine -monthsended September 30, 2024, we obtained net cash from financing activities of $1.8 million compared to $3.6 million for the same period in 2023.We held cash of approximately $0.1 million as of September 30, 2024, December 31, 2023 and 2022, respectively. Additional funds may be necessary to maintain current operations and will be